Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart A Grossman

Showing results (101-110 of 171) with videos related to

Pageof 18
Sort By:
Journal of Neuro-Oncology|February 18, 2011
A radiotherapy technique to limit dose to neural progenitor cell niches without compromising tumor coverageKristin J Redmond, Pragathi Achanta, Stuart A Grossman, et al.
Neuro-Oncology|June 26, 2008
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomasStuart A Grossman, Kathryn A Carson, Surasak Phuphanich, et al.
Journal of Neuro-Oncology|September 22, 2009
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiformeMatthias Holdhoff, Jeffrey G Supko, Gary L Gallia, et al.
Journal of Neurosurgery|September 18, 2020
Quantifying the utility of a multidisciplinary neuro-oncology tumor boardAdham M Khalafallah, Adrian E Jimenez, Carlos G Romo, et al.
Neuro-Oncology|February 11, 2005
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomasStuart A Grossman, Jane B Alavi, Jeffrey G Supko, et al.
Journal of Neuro-Oncology|May 7, 2011
Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomasMichelle A Rudek, Pamela New, Tom Mikkelsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin, Rebecca A Betensky, Fred H Hochberg, et al.
Journal of Neuro-Oncology|July 31, 2017
Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomideJian L Campian, Anna F Piotrowski, Xiaobu Ye, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|May 19, 2012
Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastomaThomas W Link, Graeme F Woodworth, Kaisorn L Chaichana, et al.
Advances in Radiation Oncology|March 5, 2021
Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal MalignanciesAnirudh Yalamanchali, Hong Zhang, Ke Colin Huang, et al.
Pageof 18

Showing results (101-110 of 171) with videos related to

Sort By:
Pageof 18
Journal of Neuro-Oncology|February 18, 2011
A radiotherapy technique to limit dose to neural progenitor cell niches without compromising tumor coverageKristin J Redmond, Pragathi Achanta, Stuart A Grossman, et al.
Neuro-Oncology|June 26, 2008
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomasStuart A Grossman, Kathryn A Carson, Surasak Phuphanich, et al.
Journal of Neuro-Oncology|September 22, 2009
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiformeMatthias Holdhoff, Jeffrey G Supko, Gary L Gallia, et al.
Journal of Neurosurgery|September 18, 2020
Quantifying the utility of a multidisciplinary neuro-oncology tumor boardAdham M Khalafallah, Adrian E Jimenez, Carlos G Romo, et al.
Neuro-Oncology|February 11, 2005
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomasStuart A Grossman, Jane B Alavi, Jeffrey G Supko, et al.
Journal of Neuro-Oncology|May 7, 2011
Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomasMichelle A Rudek, Pamela New, Tom Mikkelsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin, Rebecca A Betensky, Fred H Hochberg, et al.
Journal of Neuro-Oncology|July 31, 2017
Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomideJian L Campian, Anna F Piotrowski, Xiaobu Ye, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|May 19, 2012
Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastomaThomas W Link, Graeme F Woodworth, Kaisorn L Chaichana, et al.
Advances in Radiation Oncology|March 5, 2021
Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal MalignanciesAnirudh Yalamanchali, Hong Zhang, Ke Colin Huang, et al.
Pageof 18